Keywords: persistent antihypertensive effect, spontaneously hypertensive rat, withdrawal of treatment Abstract We have investigated whether the angiotensin II type-1 (AT 1 ) receptor antagonist, candesartan cilexetil, has a persistent effect on blood pressure even after withdrawal of treatment, as has been shown consistently for angiotensin-converting enzyme inhibitors (ACE-1). Spontaneously hypertensive rats (SHR) were divided into four groups (n=16 per group) and treated with candesartan cilexetil (high-dose: 5 mg/kg/day; middledose: 1 mg/kg/day; low-dose: 0.5 mg/kg/day) or control from age four weeks to 20 weeks. Normotensive Wistar-Kyoto rats (WKY) were also investigated. The drug was given in the drinking water, the concentration adjusted for water consumption and rat weight. Blood pressure (BP) was measured regularly by the indirect tail-cuff method during the treatment period and after treatment, from age 20 weeks to 32 weeks.
Introduction
It is normally considered that antihypertensive treatment is symptomatic, and that it is life-long. There is, however, clear evidence from the spontaneously hypertensive rat (SHR) model that limited treatment with an angiotensin-converting enzyme inhibitor (ACE-I) has a persistent hypotensive effect even after withdrawal of treatment. Thus, treatment of SHR for a few months with captopril, 1 perindopril 2-4 or cilazapril 5 from the age of about four weeks prevents blood pressure (BP) rising to control (untreated) levels when the treatment is stopped, BP remaining 15-25% below control levels for up to 12 weeks after treatment withdrawal. The time-window for this effect is thought to be prior to maturity. 3 The effect appears to be specific, in that persistent effects are not seen following treatment with other antihypertensive agents such as hydralazine, calcium channel blockers or beta-blockers. 1, 2 The mechanism for this phenomenon remains unknown, but is thought to be mediated through ACE-I treatment causing a structurally-mediated vasodilatation of the renal afferent arterioles, 5, 6 consistent with the apparent ability of these drugs to cause a particularly large reduction in renal vascular resistance. 7 The above results suggest that the persistent effect is due to specific inhibition of the reninangiotensin-aldosterone system (RAAS), and, therefore, that other agents which inhibit the system should also show persistent hypotensive effects. Indeed, it has been shown that angiotensin II receptor antagonists (AT 1 -antagonists) such as losartan 8 and L158-809 9 also have persistent effects on BP when treatment is withdrawn. The present work was initiated to determine if another AT 1 -antagonist, candesartan cilexetil, which also causes renal vasodilatation, 10 also has a persistent effect on BP when treatment is withdrawn. The protocol followed was similar to that previously used by our group with the ACE-I cilazapril, in which SHR were treated (here with three different doses of candesartan) from age four weeks to 20 weeks, and followed for a further 12 weeks after withdrawal of treatment. 5
Methods

Animals
Four-week old male SHR and Wistar-Kyoto (WKY) rats were obtained from the Møllegaard Breeding Centre (Ll. Skensved, Denmark) and kept in pairs in polycarbonate cages (0.15 x 0.25 x 0.40 m) with sawdust bedding, at a constant temperature of 20 o C to 21 o C and artificial light from 0700-1900 hours.
Medication
SHR were divided into four groups and treated with candesartan cilexetil in three doses (high-dose: 5 mg/kg/day; medium-dose: 1 mg/kg/day; low-dose: 0.5 mg/kg/day) or control.WKY rats were also investigated.There were 16 rats per group.The rats were treated from age four weeks to 20 weeks.The drug was given in the drinking water, to which the rats had free access. According to an AstraZeneca special procedure, fresh water solutions were prepared once a week, and the rats were weighed once a week during the treatment period. Drug concentrations were adjusted so that the doses (calculated as mg/kg/day) were kept constant, regardless of water consumption and rat weight. At age 20 weeks, the treatment was stopped, and the rats were followed for a further 12 weeks as previously described. 5
Blood pressure measurements Systolic BP was monitored non-invasively by the indirect tail-cuff method, and the heart rate was recorded simultaneously every one to four weeks, according to a pre-determined schedule, during the treatment period and after treatment from age 20 weeks to 32 weeks (see Figure 1 ). Each measurement was the mean of a minimum of five determinations made during a 20 minute period while the rats were quiescent.
Statistics
All results are presented as mean±SEM. Differences in body weight, heart rate and BP between groups were tested by one-way ANOVA (modified by the Bonferroni method, INSTAT). p<0.05 was considered statistically significant.
Results
During the treatment period ( Figure 1A ), candesartan caused a slight reduction in body weight at the highest dose ( Figure 1B) , a dose-dependent reduction in heart rate ( Figure 1C) , and a dosedependent reduction in BP (Table 1, Figure 1D ). Water consumption was significantly increased only in the high-dose candesartan group compared with control SHR at 20 weeks of age (WKY, 430±40 µl/kg; SHR control, 610±40 µl/kg; SHR high, 740±7 µl/kg; SHR medium, 600±20 µl/kg; SHR low, 660±30 µl/kg). Following withdrawal of treatment, heart rate returned to control levels ( Figure 1C ), whilst the slight growth inhibition in the high-dose candesartan group persisted ( Figure   1B ). There was also a persistent effect on BP after withdrawal of treatment, although in the low-dose treated group it was less marked, and not significantly different to control SHR or to the other two treated groups at 32 weeks (Table 1, Figure 1D ). At the end of the withdrawal period the BP reductions in the medium-and high-dose treated groups were 8% and 11%, respectively.
Discussion
The main finding of this study is that candesartan has a dose-dependent effect on the BP of SHR during treatment and that, at moderate to high doses, the effect persists after treatment withdrawal.
Renal basis for the persistent effect of ACE-I
An important role for the renal afferent arteriole has been implicated in ACE-inhibition. ACE-I increase renal blood flow and glomerular filtration rate and decrease renal vascular resistance in SHR, other vascular beds being less affected. 7 Furthermore, ACE-I cause greater structural vasodilation in renal afferent arterioles than do calcium channel blockers. 5 It is thus plausible that the ability of ACE-I treatment to cause a persistent reduction in BP in SHR is related to its structurally-mediated vasodilator action on the renal afferent arterioles.
That structurally-mediated vasodilation could be important is supported by the fact that increased renal vascular resistance is present in the pre-hypertensive state 11 and appears to be caused predominantly by a narrowing of the afferent arteriole. 12, 13 Evidence has also been provided that a narrowed afferent arteriole in young animals is a predictor for the later development of hypertension. 14 These findings are in agreement with renal transplant studies, where transplantation of kidneys from hypertensive animals to normotensive animals causes these to become hypertensive. [15] [16] [17] The degree to which ACE-I treatment produces a persistent reduction in BP through inhibition of the RAAS alone remains unclear. To some extent, but not entirely, these effects may be due to the effects of ACE-inhibition on the kinin-kallikrein system, since blockade of bradykinin B 2 -receptors reduced the persistent effects of ACE-I. [18] [19] [20] Charchar et al. 20 have provided evidence indicating that ACE-I causes long-term reduction in renalnerve-growth factor mRNA levels, such that the treatment may cause an effective partial renal sympathectomy. This effect was independent of the kallikrein-kinin system. In any event, ACE-I treatment results in a shift in the pressure-natriuresis relationship, consistent with the observed changes in renal medullary haemodynamics. 21 The important role of angiotensin II in the control of renal blood flow has recently been emphasised. 22 Taken together, these results suggest that the renal afferent arteriole plays a key role in the pathogenesis of hypertension in the SHR, and that the persistent effect of ACE-I is due to their ability to cause a specific, structurally-mediated, dilatation of renal afferent arterioles.
Persistent antihypertensive effects of AT 1antagonists
With AT 1 -antagonist treatment of SHR, there are two reports indicating that, as for ACE-I treatment, there is a qualitatively similar persistent effect (losartan; 8 L158-809 9 ). In the present study, the two highest doses of candesartan also showed a persistent hypotensive effect, but the effect was modest (8-11%), the level being closer to the untreated SHR than the WKY levels. The BP obtained was similar for all three doses. The magnitude of the persistent effect was less than that reported in the literature for ACE-inhibition in SHR (15-25%), 23 consistent with the view that the persistent hypotensive effect of ACE-I is not mediated through RAAS inhibition alone. [18] [19] [20] In contrast, preliminary data 24 have directly compared enalapril and losartan, and found no difference in their hypotensive effects. Therefore, it remains unclear whether ACE-I and AT 1 -antagonists have quantitatively-similar persistent effects.
The possible clinical significance of the persistent effect of inhibition of the RAAS in the SHR is, at present, speculative. Corresponding persistent effects are not seen in other models of hypertension, such as the Milan hypertensive rat, 25 suggesting that only specific forms of genetic hypertension show these effects. Nevertheless, the SHR may, in this respect, be a good model for human essential hypertension, since the human kidney also appears to play a key role in the development of hypertension. 26 In summary, treatment of SHR with candesartan for four months, from the age of four weeks has, as previously shown for ACE-I and other AT 1 -antagonists, a persistent effect on BP after treatment is withdrawn. The magnitude of this persistent effect was less than that previously reported for ACE-I. 
